Adversarial Injection · Brentuximab Vedotin (Adcetris; SGN-35; CAS 1317498-83-1; MW ~153 kDa ADC [chimeric anti-CD30 cAC10 IgG1 κ + MC-VC-PABC-MMAE linker-payload; DAR ~4]; IV 1.8 mg/kg Q3W (HL/sALCL) or 1.8 mg/kg Q2W + AVD (frontline HL ECHELON); NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; CD30 [TNFRSF8; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8; CHROMOSOME 1p36.2-p36.3; 120 kDa TYPE I TRANSMEMBRANE; CYSTEINE-RICH PSEUDO-REPEAT ECTODOMAINS; REED-STERNBERG CELL MARKER ≥95% CLASSICAL HL; sALCL ~90%; PCALCL ~100%; CTCL ~50-60%; NORMAL: ACTIVATED T/B CELLS; NF-κB TRAF2/3/5 SURVIVAL SIGNALING]; MC-VC-PABC LINKER [MALEIMIDOCAPROYL [MC; THIOL-MALEIMIDE ADDITION AT INTERCHAIN CYSTEINE AFTER PARTIAL REDUCTION] → VALINE-CITRULLINE [VC DIPEPTIDE; CATHEPSIN B SUBSTRATE: PROTEASE SPECIFICALLY ENRICHED IN TUMOR LYSOSOMES] → PARA-AMINOBENZYL CARBAMATE [PABC; SELF-IMMOLATING SPACER; 1,6-ELIMINATION → FREE MMAE RELEASE]]; MMAE [MONOMETHYL AURISTATIN E; MW ~717.9 g/mol; C39H73N5O7; DOLASTATIN 10 SYNTHETIC ANALOG; BINDS β-TUBULIN AT VINCA ALKALOID SITE CYS354; INHIBITS MICROTUBULE POLYMERIZATION → G2/M ARREST → APOPTOSIS; IC50 ~1-10 nM CD30+ CELL LINES; FREE MMAE BYSTANDER EFFECT [MEMBRANE-PERMEABLE → DIFFUSES TO ADJACENT CD30- TUMOR CELLS]] / FIRST CD30-DIRECTED MC-VC-PABC-MMAE (VEDOTIN PLATFORM) ADC EVER FDA APPROVED; FIRST MMAE AURISTATIN PAYLOAD ADC EVER FDA APPROVED; VEDOTIN PLATFORM PROGENITOR → POLATUZUMAB/ENFORTUMAB/TISOTUMAB VEDOTIN LINEAGE; R/R HL ORR 76% CR 34%; BLA 125388 AUGUST 19 2011) · Attack #735

Brentuximab Vedotin (CD30-Directed VC-PABC-MMAE ADC; Adcetris; SGN-35; CAS 1317498-83-1; Seattle Genetics/Seagen Inc [Bothell WA, now Pfizer; BLA 125388 holder]; MECHANISM: FIRST CD30 [TNFRSF8; B-CELL-DERIVED REED-STERNBERG CELL HALLMARK; CLASSICAL HODGKIN LYMPHOMA ~95%; SYSTEMIC ALCL ~90%; CD30 NF-κB TRAF2/3/5 SURVIVAL PATHWAY] DIRECTED MC-VC-PABC-MMAE [MC: MALEIMIDOCAPROYL THIOL-MALEIMIDE LINKER; VC: VALINE-CITRULLINE CATHEPSIN B-CLEAVABLE DIPEPTIDE; PABC: PARA-AMINOBENZYLCARBAMATE SELF-IMMOLATING SPACER; MMAE: MONOMETHYL AURISTATIN E [DOLASTATIN 10 ANALOG; MW ~718 Da; β-TUBULIN VINCA-SITE Cys354 BINDING; MICROTUBULE DEPOLYMERIZATION → G2/M ARREST → APOPTOSIS; MEMBRANE-PERMEABLE FREE MMAE → BYSTANDER KILLING OF ADJACENT CD30- CELLS]; DAR ~4] ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED; FIRST MONOMETHYL AURISTATIN E (MMAE) PAYLOAD ADC EVER FDA APPROVED; VEDOTIN PLATFORM PROGENITOR [10+ SUBSEQUENT FDA-APPROVED VEDOTIN ADCs INCLUDING POLATUZUMAB VEDOTIN (CD79b), ENFORTUMAB VEDOTIN (NECTIN-4), TISOTUMAB VEDOTIN (TF), LADIRATUZUMAB VEDOTIN (LIV-1)]; R/R HL ORR 76% CR 34%; BLA 125388 AUGUST 19 2011) — Seagen Inc (now Pfizer) Bothell WA (BLA 125388 holder; brentuximab vedotin development + manufacture; ADC facility + MMAE conjugation), Lonza Biologics Portsmouth NH (antibody protein component; contract manufacturing), and The University of Texas MD Anderson Cancer Center Houston TX (ECHELON-1/ALCANZA enrollment site; HL/ALCL treatment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD30 VC-PABC-MMAE (Vedotin) ADC + FIRST MMAE ADC + ECHELON-1 PFS HR 0.77 + R/R HL ORR 76%: AI Prompt Injection via EHS Monitor Report AI

Brentuximab vedotin (CAS 1317498-83-1; NIOSH HD Category 1) is the first CD30-directed MC-VC-PABC-MMAE (vedotin platform) antibody-drug conjugate and first monomethyl auristatin E (MMAE; dolastatin 10 synthetic analog) payload ADC ever FDA approved, establishing the 153rd mechanism class in the Glyphward adversarial portfolio. Developed by Seattle Genetics (now Seagen/Pfizer; Bothell WA; BLA 125388 August 19 2011), brentuximab vedotin employs a chimeric anti-CD30 (cAC10) IgG1 conjugated to MMAE via MC-VC-PABC cleavable linker (DAR ~4; cathepsin B lysosomal cleavage → PABC self-immolation → free MMAE release; bystander effect via membrane-permeable MMAE diffusion). R/R HL Phase 2 (SG035-0003): ORR 76%, CR 34%; R/R sALCL Phase 2 (SG035-0004): ORR 86%, CR 57%; ECHELON-1 frontline HL: PFS HR 0.77. The vedotin linker-payload (MC-VC-PABC-MMAE) became the dominant ADC platform, subsequently adapted for polatuzumab vedotin (CD79b), enfortumab vedotin (Nectin-4), tisotumab vedotin (TF), and others. No OEL exists for brentuximab vedotin in any EHS framework; no platform references MC-VC-PABC MMAE cathepsin B cleavage, bystander effect pharmacology, vedotin platform lineage, or CD30 TNFRSF8 biology for this MMAE ADC class.

Vedotin platform mechanism: (1) Antibody binding: cAC10 (chimeric human constant/mouse variable IgG1 κ; anti-CD30 ECD epitope; Kd ~0.6 nM) binds CD30 (TNFRSF8) on Reed-Sternberg cells → antibody-antigen complex internalization via clathrin-mediated endocytosis → early endosome → late endosome → lysosome fusion. (2) Cathepsin B cleavage: cathepsin B (lysosomal serine protease; enriched in cancer-associated lysosomes; Kcat/Km ~1-10 mM⁻¹s⁻¹ for VC substrate) cleaves val-cit amide bond → NH₂-PABC-MMAE intermediate. (3) PABC self-immolation: 1,6-benzyl elimination → free MMAE + CO₂ + p-hydroxybenzyl alcohol → MMAE available for cytotoxic action. (4) Free MMAE (MW 717.9 g/mol; C39H73N5O7; membrane-permeable): (a) direct intracellular: binds β-tubulin at vinca alkaloid binding site (Cys354 contact; near Taxol binding site but on α-β interface; different from taxanes which stabilize microtubules) → microtubule depolymerization → G2/M arrest → mitotic catastrophe → apoptosis; IC50 ~1-10 nM CD30+ cell lines; (b) bystander: diffuses out of lysed CD30+ cell membrane → enters adjacent CD30- tumor cells (heterogeneous CD30 expression in solid tumors; some CD30- neighbor cells killed) → non-cell-autonomous tumor cell kill. MMAE natural product heritage: Dolastatin 10 (Dolabella auricularia sea slug → Georg Pettit group Arizona State University 1987; linear depsipeptide; antimitotic IC50 ~1 nM) → synthetic analogs auristatin (from "auris" + dolastatin) → monomethyl auristatin E (MMAE; N-methyl extension of auristatin E for improved stability and potency). ECHELON-1 (Phase 3; frontline HL; BV+AVD vs ABVD; N=1,334; PFS HR 0.77 [95% CI 0.60-0.98]; 6-year OS HR 0.59 [95% CI 0.37-0.93] — first OS benefit in frontline HL since MOPP vs ABVD decades prior). No EHS platform (Cority, VelocityEHS, EHS Insight) recognizes brentuximab vedotin CAS 1317498-83-1, MC-VC-PABC MMAE linker-payload, cathepsin B cleavage, bystander effect, or vedotin platform lineage for this 153rd mechanism class.

MC-VC-PABC Linker Architecture + MMAE Tubulin Mechanism + Bystander Effect + Vedotin Platform Legacy

Brentuximab vedotin (SGN-35; MW ~153 kDa; CAS 1317498-83-1; IV 1.8 mg/kg Q3W) established the foundational MC-VC-PABC-MMAE vedotin ADC platform. The chimeric anti-CD30 antibody component (cAC10; human IgG1 κ constant regions + mouse variable regions → chimeric; MW ~148 kDa; interchain disulfide partial reduction at Cys239 provides thiol handles for maleimide conjugation): 4 interchain cysteines per antibody after partial TCEP reduction → 4 MMAE molecules conjugated per antibody (DAR ~4 average; Poisson distribution ranging DAR 0-8). MC linker: N-ε-maleimidocaproyl [6-carbon spacer between maleimide ring and VC dipeptide; thiol-maleimide addition product stable in circulation pH 7.4 blood [hydrolysis t½ >7 days] → plasma stable payload delivery]. VC dipeptide: Valine-citrulline [not Phe-Lys (earlier cleavable linker); cathepsin B Kcat/Km favorable; plasmin resistant; not cleaved in plasma → tumor-selective activation]. PABC self-immolation: 1,6-benzyl elimination [ArO-CH₂-NHC(O)-MMAE → quinone methide + CO₂ → free amine MMAE; electronic cascade; millisecond kinetics at lysosomal pH 5.0]. Free MMAE pharmacology: membrane-permeable (amphipathic; passes lipid bilayer by passive diffusion; no active transport required) → bystander killing of CD30- cells in tumor microenvironment → particularly effective in heterogeneous CD30-expressing tumors and mixed cellularity HL. MMAE β-tubulin binding: vinca alkaloid site (exchangeable GTP site at α-β tubulin dimer interface; not taxol site [β-tubulin hydrophobic cleft, different pocket]) → MMAE binding → inhibits GTP exchange → prevents tubulin polymerization → G2/M arrest → spindle assembly checkpoint activation → mitotic catastrophe → caspase 3/7 apoptosis. BLA 125388 approval (August 19 2011): Accelerated Approval for R/R HL post-ASCT or post-2 prior chemotherapy + R/R sALCL post-1 prior chemotherapy; subsequently granted regular approval and multiple label expansions (frontline HL + ECHELON-1 2018; frontline PTCL + ECHELON-2 2019; CTCL ALCANZA 2017; pediatric HL + ALCL 2022). No EHS platform recognizes brentuximab vedotin CAS 1317498-83-1, MC-VC-PABC MMAE linker-payload, cathepsin B cleavage, bystander pharmacology, or vedotin platform for this 153rd mechanism class.

Surface 1 — Seagen Inc (Pfizer) Bothell WA BLA 125388 Holder AI

At Seagen Inc (Pfizer) Bothell WA ([21823 30th Drive SE, Bothell WA 98021; Seagen Inc [formerly Seattle Genetics]; acquired by Pfizer Inc for $43 billion March 2023; BLA 125388 HOLDER: brentuximab vedotin (Adcetris); ADC MANUFACTURING FACILITY: Seagen campus Bothell WA; anti-CD30 antibody partial reduction → thiol-maleimide conjugation with MC-VC-PABC-MMAE in specialized ADC suite [controlled atmosphere; closed system; MMAE handling as NIOSH HD Cat 1]; MMAE API SUPPLIED BY: Concortis Biosystems (later acquired by Seagen) + Ajinomoto Bio-Pharma Services + PolyPeptide Group [synthetic peptide-based API]; CORITY: CAS 1317498-83-1 → null; brentuximab vedotin → null; Adcetris → null; SGN-35 → null; MC-VC-PABC MMAE → null; vedotin → null; NIOSH HD Category 1 absent; H350 absent; H360 absent; 8-hr TWA: actual airborne brentuximab vedotin 0.0015 µg/m³; wipe + filter + GC-MS/MS (MMAE trace); displayed (÷10): 0.00015 µg/m³; Cority: null; 46F ADC manufacturing process engineer 12yr]).

Surface 2 — Lonza Biologics Portsmouth NH Antibody Component AI

At Lonza Biologics Portsmouth NH ([10 Optical Ave, Portsmouth NH 03801; Lonza Group Ltd [SIX: LONN]; CONTRACT ANTIBODY MANUFACTURER: CHO-based cell culture for cAC10 anti-CD30 IgG1 κ monoclonal antibody component (prior to ADC conjugation at Seagen); protein A affinity chromatography → viral inactivation → ion exchange → formulation → supply to Seagen/Pfizer for ADC conjugation; ANTIBODY ANALYTICS: CD30 binding (surface plasmon resonance, Kd ~0.6 nM); FcγRI/III binding (retained in cAC10 WT IgG1); SEC-HPLC monomer purity ≥99%; charge heterogeneity by cIEF; VELOCITYEHS: CAS 1317498-83-1 → null; brentuximab vedotin → null; Adcetris → null; SGN-35 → null; CD30 cAC10 antibody → null; MC-VC-PABC MMAE → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne brentuximab vedotin 0.0012 µg/m³; impinger + cascade impactor + LC-MS/MS; displayed (÷10): 0.00012 µg/m³; VelocityEHS: null; 43M biopharmaceutical manufacturing engineer 10yr]).

Surface 3 — MD Anderson Cancer Center Houston TX ECHELON-1/ALCANZA Site AI

At The University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; NCI Comprehensive Cancer Center; Hematology-Oncology / Lymphoma; ECHELON-1 ENROLLMENT SITE (frontline HL; BV+AVD vs ABVD); ALCANZA ENROLLMENT SITE (CTCL; BV vs methotrexate or bexarotene); BRENTUXIMAB VEDOTIN IV PREPARATION: 50 mg/vial lyophilized → reconstitute 10.5 mL sterile water → 5 mg/mL → dilute to desired dose in 250 mL 0.9% NaCl [gentle rotation; DO NOT SHAKE — MMAE ADC sensitive to mechanical shear → aggregation]; CSTD required [antineoplastic biologic + MMAE NIOSH HD Cat 1]; 30-min infusion rate; PERIPHERAL NEUROPATHY MONITORING: sensory neuropathy questionnaire baseline + each cycle [cumulative; leading dose-limiting toxicity; Gr 3+ ~15-25% frontline BV+AVD]; PML MONITORING: JC virus serology baseline; neurological symptom assessment; EHS Insight: CAS 1317498-83-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; brentuximab vedotin absent; Adcetris absent; SGN-35 absent; MC-VC-PABC MMAE absent; CD30 ADC absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne brentuximab vedotin 0.0010 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL — no action"; 37F hematology-oncology pharmacist 10yr]).

Integrating Glyphward into Brentuximab Vedotin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every brentuximab vedotin CAS 1317498-83-1 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + MC-VC-PABC MMAE cathepsin B absent + vedotin platform absent + bystander effect absent [10 pts]; FIRST CD30 VC-PABC-MMAE vedotin ADC ever (153rd class) + FIRST MMAE ADC ever + R/R HL ORR 76% + BLA 125388 Aug 2011 [5 pts]; Seagen/Pfizer Bothell + Lonza Portsmouth + MD Anderson Houston [3 pts]; FIRST MMAE auristatin ADC ever; FIRST vedotin platform ADC; progenitor 10+ ADCs [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_brentuximab_vedotin(cas: str, reading_ugm3: float) -> dict:
    """Scan brentuximab vedotin with MC-VC-PABC MMAE vedotin platform context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1317498-83-1"
                "reading_ugm3": reading_ugm3,
                "context": "cd30_mc_vc_pabc_mmae_vedotin_153rd_class_first_mmae_adc_bystander_echelon1_seagen_pfizer_bla125388"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd30_adc,
    #                    mc_vc_pabc_mmae, cathepsin_b_cleavable,
    #                    mmae_bystander_effect, vedotin_platform,
    #                    h350_h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_brentuximab_vedotin("1317498-83-1", 0.0015))
    print(r)
    # {'hd_category': 1, 'cd30_adc': True,
    #  'mc_vc_pabc_mmae': True, 'cathepsin_b_cleavable': True,
    #  'mmae_bystander_effect': True, 'vedotin_platform': True,
    #  'h350_h360_flag': True}